Laboratory

CNL and AECL Welcome a Record Turnout to the 2022 Open House at Chalk River Laboratories

Retrieved on: 
Monday, August 8, 2022 - 8:30pm

CHALK RIVER, Ontario, Aug. 08, 2022 (GLOBE NEWSWIRE) -- The hot and humid weather didnt deter over 3,000 visitors from taking part in what was a record turnout for the 2022 Chalk River Laboratories Open House.

Key Points: 
  • CHALK RIVER, Ontario, Aug. 08, 2022 (GLOBE NEWSWIRE) -- The hot and humid weather didnt deter over 3,000 visitors from taking part in what was a record turnout for the 2022 Chalk River Laboratories Open House.
  • To learn more about the 2022 Open House and to see photos from the event, people are encouraged to visit CNLs Facebook page.
  • With ongoing investments in new facilities and a focused mandate, Canadian Nuclear Laboratories is well positioned for the future.
  • Working with Canadian Nuclear Laboratories, AECL enables nuclear science and technology and manages the Government of Canadas radioactive waste responsibilities.

Precipio Announces Second Quarter Shareholder Update Call

Retrieved on: 
Monday, August 8, 2022 - 3:00pm

NEW HAVEN, Conn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q2-2022 shareholder update call on Monday, August 15th at 5:00 PM ET.

Key Points: 
  • NEW HAVEN, Conn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q2-2022 shareholder update call on Monday, August 15th at 5:00 PM ET.
  • All callers should ask for the Precipio Inc. conference call.
  • These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed.
  • The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.

Woodstock Sterile Solutions Fills Two Leadership Roles

Retrieved on: 
Monday, August 8, 2022 - 2:00pm

WOODSTOCK, Ill., Aug. 8, 2022 /PRNewswire/ -- Woodstock Sterile Solutions, a leading blow-fill-seal (BFS) contract development and manufacturing organization (CDMO), announced today that it has named Dr. Kuljit Bhatia as the company's first Chief Scientific Officer and Sheila Moran as its Senior Vice President of Quality. Bhatia will lead the company's New Product Development department and is part of the organization's senior staff. Moran is responsible for the strategy, direction, and execution of all aspects of the company's quality initiatives, quality control and training programs.

Key Points: 
  • I am confident that he will be a success in this new role," says Paul Josephs, Chief Executive Officer at Woodstock Sterile Solutions.
  • He has more than 25 years of experience in drug product development, having also held leadership roles at Mylan, DPT Laboratories, Nycomed/Fougera Pharmaceuticals and Medicis.
  • Prior to joining Woodstock Sterile Solutions, she served as the Vice President of Quality for Xeris Pharmaceuticals,
    For more information on Woodstock Sterile Solutions, visit https://woodstocksterilesolutions.com .
  • For 50 years, Woodstock Sterile Solutions has been recognized as a leading Blow-Fill-Seal (BFS) Contract Development and Manufacturing Organization (CDMO).

TOMI Environmental’s SteraMist Provides Protection Against Monkeypox and Other Pathogens As World Combats Increasing Frequency of Outbreaks

Retrieved on: 
Monday, August 8, 2022 - 1:30pm

The Environmental Protection Agency (EPA) listed SteraMist Binary Ionization Technology (BIT) on its Emerging Viral Pathogen (EVP) Guidance for Antimicrobial Pesticides, List Q, as an effective disinfectant against the Monkeypox virus.

Key Points: 
  • The Environmental Protection Agency (EPA) listed SteraMist Binary Ionization Technology (BIT) on its Emerging Viral Pathogen (EVP) Guidance for Antimicrobial Pesticides, List Q, as an effective disinfectant against the Monkeypox virus.
  • SteraMist BIT received the listing because it has proven efficacy on viruses that are more difficult to kill.
  • In addition, iHP technology has a long history of successfully combating pathogens causing epidemics and pandemics, including Ebola, MERS-CoV, and SARS-CoV-2.
  • Whether an outbreak or pandemic requires disinfection with fast, no-touch application or decontamination of large-scale areas, SteraMist technology provides uncompromising premium efficacy.

Thermo Fisher Scientific Launches Enhanced Applied Biosystems HIV-1 Genotyping Kit

Retrieved on: 
Monday, August 8, 2022 - 1:00pm

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its Applied Biosystems HIV-1 Genotyping Kit with Integrase, a research use only assay that examines positive samples of human immunodeficiency virus (HIV) to identify genetic variants that resist common antiretrovial therapeutics.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its Applied Biosystems HIV-1 Genotyping Kit with Integrase, a research use only assay that examines positive samples of human immunodeficiency virus (HIV) to identify genetic variants that resist common antiretrovial therapeutics.
  • The Applied Biosystems HIV-1 Genotyping Kit will analyze expanded targets associated with HIV drug resistance that include mutations in the integrase region of the pol gene on Applied Biosystems Sanger sequencing CE instrumentation.
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.
  • Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Volition Appoints DXOCRO to Spearhead U.S. FDA Strategy

Retrieved on: 
Monday, August 8, 2022 - 1:00pm

They are an ideal partner for us as we develop our FDA strategy in the United States.

Key Points: 
  • They are an ideal partner for us as we develop our FDA strategy in the United States.
  • "DXOCRO will spearhead both our clinical product development and our regulatory program in the United States, and seek to establish clinical utility for our Nu.Q products.
  • Through the conduct of Volition's clinical validation studies, we hope to validate a broad range of potential Nu.Q products and support Volition's U.S. commercialization strategy."
  • Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Frontier Dental Lab Group Partners with D&S Dental Laboratory

Retrieved on: 
Monday, August 8, 2022 - 11:00am

Frontier Dental Lab Group (Frontier or FDL Group) ( www.frontierdentallabgroup.com ), a leading dental laboratory platform, announced today that it has partnered with and made an investment in D&S Dental Laboratory, Inc. (D&S) ( https://dnsdental.com/ ), a full-service dental laboratory based in Waunakee, WI.

Key Points: 
  • Frontier Dental Lab Group (Frontier or FDL Group) ( www.frontierdentallabgroup.com ), a leading dental laboratory platform, announced today that it has partnered with and made an investment in D&S Dental Laboratory, Inc. (D&S) ( https://dnsdental.com/ ), a full-service dental laboratory based in Waunakee, WI.
  • D&S is a full-service, NADL certified dental laboratory offering a wide range of dental restoration products spanning the crown and bridge, removable, implant, and orthodontic / sleep appliance categories.
  • D&S Dental Laboratory, Inc. is a full-service dental laboratory with the ability to fulfill both general dentistry and cosmetic dentistry cases through its comprehensive product offering.
  • Frontier Dental Lab Group is a full service, multi-site laboratory group that provides high-end dental prosthetics for cosmetic dentistry (full arch, single and multi-unit anterior crowns and bridges, and veneers), general dentistry (single and multi-unit posterior crowns and bridges), implants (single unit, bridge, and full mouth) and removable dental products (dentures, custom trays, and nightguards).

UPS to Acquire Multinational Healthcare Logistics Provider Bomi Group

Retrieved on: 
Monday, August 8, 2022 - 7:00am

ATLANTA, Aug. 08, 2022 (GLOBE NEWSWIRE) -- UPS (NYSE: UPS) today announced plans to acquire Bomi Group, an industry-leading multinational healthcare logistics provider.

Key Points: 
  • ATLANTA, Aug. 08, 2022 (GLOBE NEWSWIRE) -- UPS (NYSE: UPS) today announced plans to acquire Bomi Group, an industry-leading multinational healthcare logistics provider.
  • As a leading global healthcare logistics company, Bomi enhances our portfolio of services and accelerates our journey to become the number one provider of complex healthcare logistics, said EVP and President of UPS International, Healthcare and Supply Chain Solutions Kate Gutmann.
  • We are focused on building healthcare logistics capabilities and services that allow our customers to deliver the newest healthcare innovations, said UPS Healthcare President Wes Wheeler.
  • BOMI GROUP is a leading Italian multinational company in the field of integrated logistics serving the Healthcare sector.

AnPac Bio Announces Appointment of New Directors and Co-Chief Executive Officer

Retrieved on: 
Friday, August 5, 2022 - 9:45pm

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

Key Points: 
  • This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
  • These forward-looking statements are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Companys future financial and operating performance.
  • These statements also involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to be materially different from those expressed or implied by any forward-looking statement.
  • Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements.

Two Day Course: Writing and implementing a Standard Operating Procedure (SOP) in a Compliant Laboratory (US FDA, US EPA and OSHA Focus) - August 8-9, 2022 - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022 - 1:19pm

The "Writing and implementing a Standard Operating Procedure (SOP) in a Compliant Laboratory (US FDA, US EPA and OSHA Focus) Course" training has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Writing and implementing a Standard Operating Procedure (SOP) in a Compliant Laboratory (US FDA, US EPA and OSHA Focus) Course" training has been added to ResearchAndMarkets.com's offering.
  • Any action in the laboratory must be done by following an SOP, no matter how common or seemingly trivial the action might be.
  • Know the roles within the laboratory of each individual in creating, implementing, monitoring, training, documenting, and updating an SOP.
  • The reasons why will be described, as will the steps needed to convert a standard method into a compliant SOP.